QGEN logo

Qiagen NV (QGEN) Company Overview

Profile

Full Name:

Qiagen N.V.

Sector:

Healthcare

Country:

Netherlands

IPO:

June 28, 1996

Indexes:

Not included

Description:

Qiagen NV is a global biotechnology company that provides tools and technologies for molecular diagnostics and research. They specialize in sample preparation, testing, and bioinformatics, helping scientists and healthcare professionals analyze genetic information for disease detection and treatment. Their products support advancements in personalized medicine and life sciences.

Key Details

Price

$38.55

Annual Revenue

$1.98 B(+0.66% YoY)

Annual EPS

$0.38(-75.75% YoY)

PE Ratio

103.07

Beta

0.54

Events Calendar

Earnings

Next earnings date:

Apr 29, 2025

Recent quarterly earnings:

Feb 5, 2025

Recent annual earnings:

Feb 5, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Jan 29, 2025
Splits

Next split:

N/A

Recent split:

Jan 29, 2025

Analyst ratings

Recent major analysts updates

Feb 19, 25 Baird
Neutral
Feb 7, 25 UBS
Neutral
Jan 6, 25 Morgan Stanley
Equal-Weight
Dec 10, 24 Jefferies
Buy
Oct 17, 23 JP Morgan
Overweight
Sep 26, 23 Citigroup
Buy
Sep 12, 23 Baird
Outperform
Aug 9, 23 UBS
Neutral
Feb 9, 23 UBS
Neutral
Feb 9, 23 Citigroup
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Events

Dividend per share

Dividend yield

Other

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Qiagen NV?
  • Does Qiagen NV pay dividends?
  • What sector is Qiagen NV in?
  • What industry is Qiagen NV in?
  • What country is Qiagen NV based in?
  • When did Qiagen NV go public?
  • Is Qiagen NV in the S&P 500?
  • Is Qiagen NV in the NASDAQ 100?
  • Is Qiagen NV in the Dow Jones?
  • When was Qiagen NV's last earnings report?
  • When does Qiagen NV report earnings?
  • Should I buy Qiagen NV stock now?

What is the ticker symbol for Qiagen NV?

The ticker symbol for Qiagen NV is NYSE:QGEN

Does Qiagen NV pay dividends?

Yes, Qiagen NV pays dividends. The last payment was $1.30, with an ex-dividend date on January 29, 2025

What sector is Qiagen NV in?

Qiagen NV is in the Healthcare sector

What industry is Qiagen NV in?

Qiagen NV is in the Diagnostics & Research industry

What country is Qiagen NV based in?

Qiagen NV is headquartered in Netherlands

When did Qiagen NV go public?

Qiagen NV's initial public offering (IPO) was on June 28, 1996

Is Qiagen NV in the S&P 500?

No, Qiagen NV is not included in the S&P 500 index

Is Qiagen NV in the NASDAQ 100?

No, Qiagen NV is not included in the NASDAQ 100 index

Is Qiagen NV in the Dow Jones?

No, Qiagen NV is not included in the Dow Jones index

When was Qiagen NV's last earnings report?

Qiagen NV's most recent earnings report was on Feb 5, 2025

When does Qiagen NV report earnings?

The next expected earnings date for Qiagen NV is Apr 29, 2025

Should I buy Qiagen NV stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions